Jonathan E. Lim, M.D. – Chairman
Jonathan Lim co-founded Ignyta as Chairman in August 2011 and joined full-time in July 2012 as President and Chief Executive Officer. Under his leadership, the company went public in 2013. It has raised nearly $350 million from financings and corporate transactions with Teva and Lilly and is focused on building a precision medicine company aspiring to eradicate residual disease in precisely defined cancer patient populations by 2030.
From May 2003 to December 2010, Dr. Lim was President, Chief Executive Officer, and a Director of Halozyme Therapeutics, Inc. (NASDAQ: HALO). In March 2011, Dr. Lim co-founded and most recently served as Chairman and CEO of Eclipse Therapeutics, a Biogen Idec spinout. Eclipse was successfully sold to Bionomics Ltd. (ASX:BNO) in a transaction that closed in September 2012, and Dr. Lim subsequently served as a member of the Board of Directors of Bionomics for three years, until November 2015. He is also a member of the Board of Visitors of the Moores Cancer Center at UC San Diego, a position he has held since December 2015, and an Advisory Council member of Stanford Bio-X, an initiative by Stanford University to foster interdisciplinary medical research. In February 2016, Dr. Lim joined the Board and currently serves as Chairman of Bonti, Inc., a startup developing next-generation neurotoxins for patients with unmet needs in post-surgical care and aesthetic medicine.
Dr. Lim’s prior experience also includes management consulting at McKinsey & Company, an NIH Postdoctoral Fellowship at Harvard Medical School and the Dana Farber Cancer Institute, and two years of general surgery residency at New York Hospital-Cornell and Memorial Sloan Kettering Cancer Center.
He has B.S. and M.S. degrees from Stanford, an M.D. from McGill, and an M.P.H. from Harvard.